Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-β1 in a cultured stellate cell line-Reference-Cited by-同舟云学术

Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-β1 in a cultured stellate cell line

Published:2008-10 Issue:10 Volume:38 Page:1026-1039
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:

Author:

Nakano Shigeru,Nagasawa Tatsuya,Ijiro Tomoyuki,Inada Yoichi,Tamura Toru,Maruyama Kazuyasu,Kuroda Junji,Yamazaki Yoshinobu,Kusama Hiroshi,Shibata Nobuo

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1872-034X.2008.00363.x/fullpdf

Reference55 articles.

1. Nonalcoholic steatohepatitis;Diehl;Semin Liver Dis,1999

2. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome;Marchesini;Hepatology,2003

3. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association;Pagano;Hepatology,2002

4. Steatohepatitis: a tale of two “hits”?;Day;Gastroenterology,1998

5. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference;Neuschwander-Tetri;Hepatology,2003

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Crosstalk between Lipids and Non-Alcoholic Fatty Liver Disease;Livers;2023-11-23

2. Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease;Biomolecules;2023-08-18

3. Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease;Hepatology Research;2022-11-29

4. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH);Signal Transduction and Targeted Therapy;2022-08-13

5. Is there a role of lipid-lowering therapies in the management of fatty liver disease?;World Journal of Hepatology;2022-01-27